A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Merck Sharp & Dohme LLC0 sites530 target enrollmentMarch 2006

Overview

This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Registry

clinicaltrials.gov

Start Date

March 2006

End Date

March 2007

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Responsible Party

Sponsor

•Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the values established by the study such as an Hemoglobin A1c (HbA1c) \>=7.5% and \<=11% and a Fasting Plasma Glucose (FPG) \>=130 mg/dL and \<=280 mg/dL
•Exclusion Criteria :
•Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12 months

sitagliptin 100 mg

Intervention: sitagliptin phosphate

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18

Time Frame: Baseline and Week 18

A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18(Baseline and Week 18)
Change From Baseline in 2-hr Post-Meal Glucose (PMG) at Week 18(Baseline and Week 18)